



Research Journal of Pharmaceutical, Biological and Chemical Sciences

Benzothiazole derivatives and its Biological activities: A Review

Rajinder Kumar*, Uday Kalidhar, Amandeep Kaur, Jaideep Bajaj¹

Dept of Pharmaceutical Chemistry, ASBASJSM College of Pharmacy, Bela, Ropar (Pb), India.

¹Dept of Pharmacology, Khalsa College of Pharmacy, Amritsar (Pb), India.

ABSTRACT

Different heterocyclic compounds are made to synthesize by large number of efforts and their derivatives were found to possess anti-tumor, antidiabetic, anti-microbial, anti-convulsant and anthelmintic activities. In recent years heterocyclic compounds analogues and derivatives have attracted strong interest due to their biological and pharmacological properties. Benzothiazole moiety is very small but it possesses different biological activities by not only benzothiazole but its different substituted derivatives also give different biological activities. This review was focused on the benzothiazole and its different derivatives that possess different biological activities.

Keywords: Benzothiazole, Biological activities.


**Corresponding author*

INTRODUCTION

A heterocyclic compound is one which possesses a cyclic structure with at least two different kinds of hetero atoms in the ring. Nitrogen, oxygen, and sulphur are the most common heteroatoms. Benzothiazole ring made from thiazole ring fused with benzene ring. Thiazole ring is a five-member ring consists of one nitrogen and one sulfur atom in the ring. Benzothiazoles are bicyclic ring system. In the 1950s, a number of 2-amino benzothiazoles were intensively studied as central muscle relaxants and found to interfere with glutamate neurotransmission in biochemical, electrophysiological and behavioral experiments. Benzothiazole derivatives have been studied and found to have various chemical reactivity and biological activity. Benzothiazole derivatives have been studied and found to have various chemical reactivity and biological activity. Benzothiazole ring found to be possessing pharmacological activities such as anti-bacterial [1], anti- microbial [2], anti-diabetic [3], antitumor [4], anti- inflammatory [5], anthelmintic [6] activities.


ANTIMICROBIAL ACTIVITY

Al-Tel et al., [7] synthesized a series of imidazo[2,1-b][1,3]benzothiazole. The compounds (**1 a-d**) and (**2 a-e**) were tested for their in vitro antibacterial activity against Gram-positive bacteria *S. aureus*, *E. faecalis* and *B. megaterium* and Gram-negative bacteria *E. coli*, *P. aeruginosa* and *E. aerogenes*. The antifungal activity against *C. albicans*, *C. parapsilosis*, *A. flavus* and *M. gypsuem*. The compounds have shown good activity.



(**1 a-d**)

Comp. No.	R ₁	R ₂
1a	Br	F
1b	F	F
1c	OCH ₃	F
1d	CH ₃	F




(**2 a-e**)


Comp. No.	R ₁	R ₂
2a	Br	F
2b	F	F
2c	CH ₃	F
2d	Br	OCH ₃
2e	OCH ₃	F

Sekar et al., [8] synthesized a series of 2-(1H-benzimidazol-2-yl)-5-(diethylamino)phenol, 2-(1,3-benzoxazol-2-yl)-5-(diethylamino)phenol, 2-(1,3-benzothiazol-2-yl)-5-(diethylamino)phenol. All compounds (**3a-i**) were evaluated for in vitro antibacterial activities against *Escherichia coli* and *Staphylococcus aureus* strains and in vitro antifungal activity against


Candida albicans and *Aspergillus niger* strains by using serial dilution method. The compounds have shown moderate activity.



(3 a-c)




(3 d-h)




(3 i)

Soni et al., [9] synthesized a series of 5-[2-(1,3-benzothiazol-2-yl-amino)ethyl]-4-(arylideneamino)-3-mercapto-(4H)-1,2,4-triazoles. The synthesized compounds (**4 a-g**) were screened for their antibacterial activity against *Bacillus subtilis* MTCC 441, *Escherichia coli* MTCC 443 and *Streptomyces griseus* MTCC 1540 and antifungal activity against *Candida albicans* MTCC 227 and *Aspergillus niger* MTCC 282. All the compounds tested showed some degree of antimicrobial activity.



Comp. No.	R ₁
4a	H
4b	4-OH
4c	2-NO ₂
4d	3-NO ₂
4e	2-Cl
4f	4-N(CH ₃) ₂
4g	3,4-OCH ₃

Sahu et al., [10] synthesized a series of 1,3-benzothiazole-2-yl-hydrazone (**5 a-j**). In vitro antimicrobial activity was evaluated against the four pathogenic bacterial strains, *Bacillus subtilis*, *Escherichia coli*, *Klebsiella pneumoniae* and *Pseudomonas alkaligenes* and three fungal strains *Aspergillus niger*, *Rhizopus oryzae* and *Candida albicans*. The compounds have shown moderate activity.



(5 a-j)

Comp. No.	R ₁	R ₂
5a	CH ₃	No ₂
5b	CH ₃	Br
5c	CH ₃	OCH ₃
5d	CH ₃	Cl
5e	CH ₃	OH
5f	CH ₃	NH ₂
5g	C ₆ H ₅	H
5h	CH ₃	H
5i	H	F
5j	H	CH ₃


ANTICANCER ACTIVITY

Song et al., [11] synthesized a series of α -Aminophosphonates containing benzothiazole and fluorine moiety, (**6 a-m**) were synthesized by Mannich-type addition in ionic liquid media with high yield and short reaction time. The newly synthesized compounds were evaluated for their anticancer activities against PC3, A431, A375, and Bcap37 cells in vitro by the MTT method. Compound **6c** is highly effective against PC3 cells and moderate to A431 cells.

Comp. No.	R ₁	R ₂	R ₃
6a	4-CH ₃	2-F	Et
6b	4-CH ₃	2-F	<i>n</i> -Pr
6c	4-CH ₃	2-F	<i>n</i> -Bu
6d	4-CH ₃	4-CF ₃	Me
6e	4-CH ₃	4-CF ₃	Et
6f	4-CH ₃	4-CF ₃	<i>i</i> -Pr
6g	4-CH ₃	4-CF ₃	<i>n</i> -Bu
6h	6-OCH ₃	2-F	Me
6i	6-OCH ₃	2-F	Et
6j	6-OCH ₃	2-F	<i>n</i> -Pr
6k	6-OCH ₃	2-F	<i>i</i> -Pr
6l	6-OCH ₃	2-F	<i>n</i> -Bu
6m	6-OCH ₃	2-F	Et



(6 a-m)

Prabhu et al., [12] synthesized a series of 2-(3-(4-oxo-2-substituted phenyl thiazolidin-3-yl)phenyl)benzo[d]thiazole-6-carboxylic acid derivatives (**7 a-h**) were synthesized by various benzothiazole Schiff's bases by reaction with thioglycollic acid. All the synthesized compounds were screened for their in vitro anticancer activity by 3-(4,5-dimethyl thiazole-2yl)-2,5-diphenyltetrazoliumbromide (MTT) assay on human cervical cancer cell line (HeLa) cell lines. Among these compound **7b** exhibited most significant activity as compared with **7e**, **7g** and **7h**. However, the activity was less as compared to the standard drug Cisplatin.


(7 a-h)


Comp. No.	R ₁
7a	H
7b	<i>p</i> -Cl
7c	<i>m</i> -F
7d	<i>p</i> -NO ₂
7e	<i>p</i> -OCH ₃
7f	<i>p</i> -F, <i>m</i> -OCH ₃
7g	<i>p</i> -CH ₃
7h	<i>p</i> -OH

Bhuva et al., [13] synthesized a series of novel 2-phenyl-1,3-benzothiazoles. All the compounds (**8 a-j**) were tested for their anticancer activity against MCF-7 breast cancer cell line with the MTT assay. Most of the compounds showed moderate to good anti-breast cancer activity. Anticancer activity varied with substitution on the benzothiazole nucleus with halogens and at 4 position, substitution of the 2-phenyl moiety with methyl and methoxy groups was also explored. Among the compounds tested with MTT assay, mono fluoro substitution on benzothiazole nucleus and 4-methyl variations at 2-phenyl position demonstrated highest percent growth inhibition of MCF-7 cells. Docking studies of the synthesised compounds was done on EGFR using GRIP batch docking method to study their observed activity.


(8 a-j)

Comp. No.	R ₁	R ₂
8a	6-F	Me
8b	5,6-diF	Me
8c	6-Br	OMe
8d	6-F	OMe
8e	6-Br	Me
8f	5-Br, 7-Br	OMe, OMe
8g	5-Cl, 7-Cl	OMe, OMe
8h	4-F	OMe
8i	5,6-diF	OMe
8j	4-F	Me

Vasconcelos et al., [14] synthesized a series of 2-(benzo[d]thiazol-2-yl)-8-substituted-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones (**9 a-g**) have been synthesized and evaluated for their in vitro antiproliferative activities against four human cancer cell lines: MDA-MB-435 (breast), HL-60 (leukemia), HCT-8 (colon) and SF-295 (central nervous system). The results showed that the compounds **9b** (2-(benzo[d]thiazol-2-yl)-8-methyl-2H-pyrazolo[4,3-c]-quinolin-3(5H)-one) and **9c** (2-(benzo[d]thiazol-2-yl)-8-bromo-2H-pyrazolo[4,3-c]quinolin-3(5H)-one) exhibited good cytotoxicity for three cell lines with IC₅₀ values lower than 5 µg/ml. Analysis of theoretical toxicity risks have shown medium tumorigenic and irritant risks related to **9b** and **9c** in contrast to doxorubicin, the positive control.




(**9 a-g**)

R = a: F; b: CH₃; c: Br; d: OCH₃; e: Cl; f: H; g: NO₂

ANTIINFLAMMATORY ACTIVITY

Shafi et al., [15] synthesized a series of 2-mercapto benzothiazole and 1,2,3-triazoles. The synthesized compounds have been tested for their anti-inflammatory activity by using biochemical cyclooxygenase (COX) activity assays and carrageenan-induced hind paw edema. Among the tested compounds, compound **10d** demonstrated a potent selective COX-2 inhibition with COX-2/COX-1 ratio of 0.44. Results from carrageenan-induced hind paw edema showed that compounds **10a**, **10d**, **10e** and **10f** possess significant anti-inflammatory activity as compared to the standard drug Ibuprofen.




(**10 a-j**)

R = a: *o*-Cl; b: *m*-Cl; c: *p*-Cl; d: *p*-F; e: *p*-Br; f: *p*-NO₂; g: *m*-NO₂; h: *p*-OEt; i: *o*-Me; j: H

Raghavendra et al., [16] synthesized a series of N-(benzo[d]thiazol-2-yl)-2-(piperazin-1-yl)acetamide analogs. These compounds (**11 a-l**) were evaluated for anti-inflammatory activity

by carragenan induced paw oedema method. Promising compounds were screened for toxicity by evaluating the ulcerogenic potential. Molecular docking experiments were carried out against COX-2 enzyme using Surfex-Dock GeomX programme of Sybyl software on Dell T-1500 workstation to confirm the mechanism of action of active compounds among the series. In silico study reveal the binding interactions of N-(benzo[d]thiazol-2-yl)-2-(piperazin-1-yl)acetamide analogs with COX-2 protein and is in agreement with the in vivo anti-inflammatory activity.




Comp. No.	R	R ₁	n
11a	H	H	1
11b	H	C ₂ H ₅	1
11c	H	H	2
11d	H	C ₆ H ₅	1
11e	OCH ₃	H	1
11f	OCH ₃	C ₂ H ₅	1
11g	OCH ₃	H	2
11h	OCH ₃	C ₆ H ₅	1
11i	NO ₂	H	1
11j	NO ₂	C ₂ H ₅	1
11k	NO ₂	H	2
11l	NO ₂	C ₆ H ₅	1


(11 a-l)

CYTOTOXIC ACTIVITY

Kumbhare et al., [17] synthesized a series of N-bis-benzothiazole derivatives. All the synthesized compounds were evaluated for cytotoxic activity against two human monocytic cell lines (U 937, THP-1) and a mouse melanoma cell line (B16-F10). Based on their IC₅₀ values, the majority of the benzothiazolyl thiocarbamides and N-bis-benzothiazoles had significant antiproliferative activity on U 937 and B16-F10 cells, the compounds **12b**, **12e**, **12f**, **12k**, **13c** and **13h** were found to be the most active. The present findings indicate clearly that the compound 3e exhibited more antiproliferative activity on U 937 cells than the standard molecule, etoposide. Nevertheless, these compounds have shown comparatively less cytotoxicity towards THP-1 cells.



(12 a-l)

Comp. No.	R ₁	R ₂
12a	H	H
12b	H	F
12c	H	Cl
12d	6-F	H
12e	6-F	F
12f	6-F	Cl
12g	4-Cl	H
12h	4-Cl	F
12i	6-Me	H
12j	6-Me	F
12k	6-OEt	H
12l	6OEt	F


(13 a-l)

Comp. No.	R ₁	R ₂
13a	H	H
13b	H	Cl
13c	6-F	F
13d	6-F	Cl
13e	4-Cl	F
13f	6-Me	H
13g	6-OEt	H
13h	6-OEt	F
13i	6-F	H
13j	4-Cl	H
13k	H	F
13l	6-Me	H

Venkatesh et al., [18] Two series of Benzothiazole, Quinazolinone derivatives bearing guanidinopropanoic acid (38 compounds including 27 intermediates) and one series of Schiff base derivatives (14 compounds) were synthesized. All compounds were evaluated for their cytotoxicity against human cervix cell line (HeLa) by MTT assay. Compounds **(14 a-f)** showed significant activity against HeLa with IC₅₀ range of 2–550 μM. Compound 3-(3-(6-hydroxybenzo[d]thiazol-2-yl)guanidino)propanoic acid **14f** showed potent activity against human HeLa cell line with the half maximal inhibitory concentration (IC₅₀) values of 1.8 μM which was close to the value of the positive control, doxorubicin.



(14 a-f)

R = a:NO₂; b: Br; c: COOH; d: Cl; e: SO₂NH₂; f: OH

ANTICONVULSANT ACTIVITY

Siddiqui et al., [19] synthesized a series of 1,3-benzothiazol-2-yl semicarbazones **(15 a-o)**. All the synthesized compounds were evaluated for anticonvulsant activity. Majority of the compounds were active in MES screen. Results indicate that the compounds possessed marked


anticonvulsant activity as indicated by their prevention of the effects of maximal electroshock induced seizures in comparison with standard drug.



(15 a-o)

Comp. No.	R	R ₁	R ₂
15a			
15b	Cl	CH ₃	H
15c	Cl	CH ₃	OH
15d	Cl	CH ₃	NO ₂
15e	Cl	CH ₃	OCH ₃
15f	Cl	C ₆ H ₅	H
15g	CH ₃	CH ₃	H
15h	CH ₃	CH ₃	OH
15i	CH ₃	CH ₃	NO ₂
15j	CH ₃	CH ₃	OCH ₃
15k	CH ₃	C ₆ H ₅	H
15l	CH ₃ O	CH ₃	H
16l	CH ₃ O	CH ₃	OH
15m	CH ₃ O	CH ₃	NO ₂
15n	CH ₃ O	CH ₃	OCH ₃
15o	CH ₃ O	C ₆ H ₅	H


Rana et al., [20] synthesized a series of 1,3-benzothiazol-2-yl benzamides. All the synthesized compounds were evaluated for anticonvulsant activity. Majority of the compounds were active in MES and scPTZ screen and showed the decrease in the immobility time.



R = Br, Cl, F, NO₂, CH₃, OCH₃
 R₁ = H, 2-Cl, 4-Cl, 4-OCH₃



ANTIOXIDANT ACTIVITY

Guzel et al., [21] synthesized a series of 3H-Spiro[1,3-benzothiazole-2,30-indol]-20(10H)-ones (**17 a-h**). The new compounds were screened for their antioxidant activities such as the Fe³⁺/ascorbate system induced inhibition of lipid peroxidation (LP) in liposomes, trolox equivalent antioxidant capacity (TEAC), scavenging effect on diphenylpicryl hydrazine (DPPH), and reducing power. These compounds showed potent scavenging activities against DPPH and 2,20-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS⁺) radicals, reducing powers, and strong inhibitory capacity on lipid peroxidation. Compound **17d** incorporating methyl both at R₁ and R₂ was found to be the most potent antioxidant.



Comp. No.	R ₁	R ₂
17a	CH ₃	H
17b	Cl	H
17c	NO ₂	H
17d	CH ₃	CH ₃
17e	CF ₃ O	CH ₃
17f	Cl	CH ₃
17g	Br	CH ₃
17h	NO ₂	CH ₃

Rima et al., [22] synthesized a series of new compounds derived from benzothiazoles and thiadiazoles. All the synthesized compounds were screened for anticonvulsant activity. The majority of these compounds were subjected to antioxidant activity screening by determining the DPPH or ABTS free radical scavenging using simple UV spectroscopic methods. The compounds have shown good activity.




R₁ = a: H, b: CH₃, c: CH₃CH₂O

ANTI-LEISHMANIAL ACTIVITY



Delmas et al., [23] synthesized a series of (1,3-Benzothiazol-2-yl) amino-9-(10H)-acridinone derivatives. All the synthesized compounds were screened for their in vitro antileishmanial and anti-HIV activities. Antileishmanial activity was assessed on the referenced strain *L. infantum* (MHOM/FR/78/LEM75). *L. infantum* promastigotes in late log-phase were incubated in RPMI medium supplemented with 12% fetal calf serum. The addition of a benzothiazole group on a parent amino-9-(10H)-acridinone ring could enhance antileishmanial abilities.

ANTI-DIABETIC ACTIVITY

Moreno-Diaz et al., [24] synthesized a series of N-(6-Substituted-1,3-benzothiazol-2-yl)benzenesulfonamide derivatives (**24 a-h**). These compounds were evaluated for their in vivo antidiabetic activity in a non-insulin-dependent diabetes mellitus rat model. Several compounds synthesized showed significant lowering of plasma glucose level in this model. As a possible mode of action, the compounds were in vitro evaluated as 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1) inhibitors. The most active compounds **24c** and **24d** were docked into the crystal structure of 11 β -HSD1. Docking results indicate potential hydrogen bond interactions with catalytic amino acid residues.



R = a: H, b: R₁, c: R₂, d: R₃





Comp. No.	R ₁	R ₂
24a	NO ₂	OCH ₃
24b	NO ₂	NHCOCH ₃
24c	OCH ₃	H
24d	OCH ₃	NO ₂
24e	OCH ₂ CH ₃	NO ₂
24f	OCH ₂ CH ₃	CH ₃
24g	CH ₃	Cl
24h	CH ₃	NO ₂

(24 a-h)


ANTHELMINTIC ACTIVITY

Munirajasekhar et al., [25] synthesized a series of 6-substituted-2-hydrazino-1,3-benzothiazoles (**25 a-e**). All the synthesized compounds were evaluated for anthelmintic activity against *Eudrilus eugeniae* species and *Megascolex konkanensis*.




R = a: H, b: CH₃, c: OCH₃, d: Cl, e: F

Suresh et al., [26] synthesized a series of 3-(2-hydrazino benzothiazoles)-substituted Indole-2-one. All the synthesized compounds were screened (**26 a-f**) and (**27 a-f**) for anthelmintic activity by using Indian adult earthworms (*pheretima postuma*). The compounds **26d**, **26f**, **27d** have showed good paralytic time, compared to standard albendazole drug.



(26 a-f)



(27 a-f)

R = a: H, b: 5-COOH, c: 5-CH₃, d: 5-Cl, e: 5-NO₂, f: 5-Br

REFERENCES

- [1] Russo F, Santagati M. *Farmaco Ed Sci* 1976; 31: 41.
- [2] Ghoneim KM, Basil S, Osman AN, Said MM, Megahed SA. *Rev Roum Chim* 1991; 36: 1355.
- [3] Pattan SR, Suresh C, Pujar VD, Reddy VVK, Rasal VP, Kotti BC. *Ind J Chem* 2005; 4B: 2404.
- [4] Yoshida M, Hayakawa I, Hyashi N, Agatsuma T, Oda Y, Tanzawa F et al. *Bioorg Med Chem Letters* 2005; 15: 3328.
- [5] Sawhney SN, Bansal OP. *Ind J Chem* 1977; 15B: 121.
- [6] Brown HD. *Chem Abstr* 65: 18593.
- [7] Al-Tel TH, Al-Qawasmeh Ra, Zaarour R. *Eur J Med Chem* 2011; 46: 1874-1881.
- [8] Sekar N, Padalkar VS, Borse BN, Gupta VD, Phatangare KR, Patil VS, Umape PG. *Arabian J Chem* 2012; doi:10.1016/j.arabjc.2011.12.006.
- [9] Soni B, Ranawat MS, Sharma R, Bhandari A, Sharma S. *Eur J Med Chem* 2010; 45: 2938-2942.
- [10] Sohu NK, Asati V, Rathore A, Sohu S, KOhli DV. *Arabian J Chem* 2011; doi:10.1016/j.arabjc.2011.01.036.
- [11] Song B, Jin L, Zhang G, Xu R, Zhang S, Gao X, Hu D, Yang S. *Bioorg Med Chem Letters* 2006; 16: 1537-1543.
- [12] Prabhu PP, Panneerselvam T, Shastry CS, Sivakumar A, Pande SS. *J Saudi Chem Soc* 2012; doi:10.1016/j.jscs.2012.02.001.
- [13] Bhuva HA, Kini SG. *J Mol Graph Mod* 2010; 29: 32-37.
- [14] Vasconcelos TRA, Reis RDR, Azevedo EC, Souza MCBV, Ferreira VF et al. *Eur J Med Chem* 2011; 46: 1448-1452.
- [15] Shafi S, Alam MM, Mulakayala N, Mulakayala C, Vanaja G, Kalle AM, Pallu R, Alam MS. *Eur J Med Chem* 2012; 49: 324-333.
- [16] Raghavendra NM, Jyothsna A, Rao AV, Subrahmanyam CVS. *Bioorg Med Chem Letters* 2012; 22: 820-823.
- [17] Kumbhare RM, Dadmal T, Kosurkar U, Sridhar V, Rao JV. *Bioorg Med Chem Letters* 2012; 22: 453-455.
- [18] Venkatesh P, Tiwari VS. *Arabian J Chem* 2011; doi: 10.1016/j.arabj.2011.09.004.
- [19] Siddiqui N, Rana A, Khan SA, Bhat MA, Haque SE. *Bioorg Med Chem Letters* 2007; 17: 4178-4182.
- [20] Rana D, Siddiqui N, Khan SA, Haque SE, Bhat MA. *Eur J Med Chem* 2008; 43: 1114-1122.
- [21] Guzel O, Karali N, Ozsoy N, Ozbey S, Slman A. *Eur J Med Chem* 2010; 45: 1068-1077.



- [22] Rima G, Cressier D, Prouillac C, Hernandez P, Amourette C, Diserbo M, Lion C. *Bioorg Med Chem* 2009; 17: 5275-5284.
- [23] Delmas F, Avellaneda A, Giorgio CD, Robin M, Clercq ED, Timon-David P, Galy JP. *Eur J Med Chem* 2004; 39: 685-690.
- [24] Moreno-Diaz H, Villalobos-Molina R, Ortiz-Andrade R, Diaz-Coutino D et al. *Bioorg Med Chem Letters* 2008; 18: 2871-2877.
- [25] Munirajasekhar D, Himaja M, Mali SV, Karigar A, Sikarwar M. *J Pharm Research* 2011; 4(7): 2186-2187.
- [26] Suresh CH, Rao JV, Jayaveera KN, Subudhi SK. *Int Res J Pharm* 2011; 2(3): 257-261.